RG
HAE icon

Renaissance Group’s Haemonetics HAE Stock Holding History

Renaissance Group’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-6,857
Closed -$614K – 239
2020
Q2 		$614K Buy
6,857
+203
+3% +$20.5K 0.03% 176
2020
Q1 		$663K Buy
+6,654
New +$722K 0.04% 141

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Group's HAE Position: Q3 2020 in Review

Renaissance Group sold out of Haemonetics (HAE) in Q3 2020, closing a stake of 6,857 shares — an estimated $614K sold.

Renaissance Group first reported a position in HAE in Q1 2020 and held it in 2 quarters. The position peaked at $663K in Q1 2020. 268 funds tracked by Wall St. Rank hold HAE as of Q3 2020.

  • Renaissance Group reported no remaining Haemonetics position as of Q3 2020 after selling out during the quarter.
  • Renaissance Group sold 6,857 Haemonetics shares in Q3 2020, an estimated $614K.
  • Renaissance Group first reported a position in Haemonetics in Q1 2020 and held it in 2 quarters.
  • Renaissance Group's Haemonetics position peaked at $663K in Q1 2020.
  • 268 funds tracked by Wall St. Rank held Haemonetics as of Q3 2020.

Based on Renaissance Group's 13F filing for Q3 2020, filed 12 Nov 2020.